EP3317246A4 - Specific conjugation of a cell-binding molecule - Google Patents

Specific conjugation of a cell-binding molecule Download PDF

Info

Publication number
EP3317246A4
EP3317246A4 EP15772625.8A EP15772625A EP3317246A4 EP 3317246 A4 EP3317246 A4 EP 3317246A4 EP 15772625 A EP15772625 A EP 15772625A EP 3317246 A4 EP3317246 A4 EP 3317246A4
Authority
EP
European Patent Office
Prior art keywords
cell
binding molecule
specific conjugation
conjugation
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP15772625.8A
Other languages
German (de)
French (fr)
Other versions
EP3317246A2 (en
Inventor
Robert Yongxin Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sushou M conj Biotech Co Ltd
Original Assignee
Sushou M conj Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sushou M conj Biotech Co Ltd filed Critical Sushou M conj Biotech Co Ltd
Publication of EP3317246A2 publication Critical patent/EP3317246A2/en
Publication of EP3317246A4 publication Critical patent/EP3317246A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/20—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP15772625.8A 2015-07-04 2015-07-04 Specific conjugation of a cell-binding molecule Pending EP3317246A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2015/055051 WO2015151080A2 (en) 2015-07-04 2015-07-04 Specific conjugation of a cell-binding molecule

Publications (2)

Publication Number Publication Date
EP3317246A2 EP3317246A2 (en) 2018-05-09
EP3317246A4 true EP3317246A4 (en) 2019-02-27

Family

ID=54241397

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15772625.8A Pending EP3317246A4 (en) 2015-07-04 2015-07-04 Specific conjugation of a cell-binding molecule

Country Status (5)

Country Link
EP (1) EP3317246A4 (en)
JP (1) JP6700321B2 (en)
CN (2) CN113698335A (en)
CA (1) CA2991384C (en)
WO (1) WO2015151080A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
CA2954934C (en) 2014-06-30 2023-09-26 Glykos Finland Oy Drug derivative and conjugates
JP7330515B2 (en) * 2015-08-10 2023-08-22 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． Novel conjugates and their use in specific conjugation of biomolecules and drugs
JP6817288B2 (en) * 2015-08-10 2021-01-20 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． Its use in novel conjugates and specific conjugation of biomolecules with drugs
US11129910B2 (en) * 2016-02-04 2021-09-28 Hangzhou Dac Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
EP3484518B1 (en) 2016-07-07 2024-08-14 The Board of Trustees of the Leland Stanford Junior University Antibody adjuvant conjugates
CN106474147B (en) * 2016-10-14 2022-07-05 上海颉隆投资管理有限公司 Dressing for preventing and controlling human papilloma virus infection and preparation method thereof
CN110099682B (en) * 2016-11-14 2023-03-31 杭州多禧生物科技有限公司 Coupled connector, cell binding molecule-drug conjugate containing same, and preparation and application thereof
JP7300394B2 (en) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー Protein kinase inhibition to promote liver regeneration or reduce or prevent hepatocyte death
CN109444349B (en) * 2018-12-26 2020-07-07 中国科学院地球化学研究所 Method for measuring metabolic water utilization share and actual water demand of indoor plant
CN113993549A (en) 2019-03-15 2022-01-28 博尔特生物治疗药物有限公司 Immunoconjugates targeting HER2
CN111773183B (en) * 2019-04-04 2022-02-01 沈阳药科大学 Cu (DDC)2Nano nuclear liposome and preparation method and application thereof
CN113811333B (en) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 Compounds targeting anti-cancer nuclear hormone receptors
US20230025327A1 (en) 2019-06-29 2023-01-26 Hangzhou Dac Biotech Co., Ltd. Conjugates of tubulysin derivatives and cell binding molecules and methods of making
CN110308145A (en) * 2019-07-10 2019-10-08 迪瑞医疗科技股份有限公司 A kind of chlamydia trachomatis glycogen detection reagent, chlamydia trachomatis glycogen test strip and preparation method thereof
CN112341521B (en) * 2019-08-09 2024-06-25 上海翰森生物医药科技有限公司 Small molecule active compound and antibody conjugate thereof, preparation method and medical application thereof
TW202131930A (en) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 Anti-cancer nuclear hormone receptor-targeting compounds
CN110835405B (en) * 2019-11-28 2020-09-15 安阳师范学院 Polymer biosensor for tumor detection and preparation method and application thereof
CN111879684B (en) * 2020-06-18 2021-12-21 山东大学 Phagocyte function detection method based on flow cytometry
CN113925973A (en) * 2020-07-14 2022-01-14 辽宁中健医药科技有限公司 Polypeptide coupled drug, preparation method and application thereof
CN112409242B (en) * 2020-09-25 2022-07-12 华南农业大学 Amlodipine hapten, artificial antigen, antibody and preparation method and application thereof
CN112379029B (en) * 2020-11-10 2022-03-08 苏州艾迪迈医疗科技有限公司 Method for detecting concentration of anti-novel coronavirus drug in blood
EP4297783A1 (en) * 2021-02-23 2024-01-03 Children's Medical Center Corporation Intercellular adhesion molecule 1 (icam1) antibody drug conjugate and uses thereof
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113214403B (en) * 2021-04-25 2023-06-09 重庆威斯腾前沿生物研究院有限责任公司 Streptavidin magnetic bead and preparation method thereof
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113913535A (en) * 2021-11-30 2022-01-11 江西农业大学 Causal gene for identifying blue peacock white feather character and application thereof
WO2023125349A1 (en) * 2021-12-27 2023-07-06 山东先声生物制药有限公司 Anti-gucy2c antibody and application thereof
CN116239513B (en) * 2023-05-05 2023-08-18 天津凯莱英制药有限公司 Preparation method of MMAE key intermediate, preparation method of MMAE and antibody coupling drug
CN116813710B (en) * 2023-07-05 2024-07-12 重庆药友制药有限责任公司 Preparation method of carfilzomib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101723961A (en) * 2009-12-08 2010-06-09 刘超美 Beta-lactam twin antibiotic compound, preparation method thereof and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228358D0 (en) * 2002-12-05 2003-01-08 Unilever Plc Improvements relating to fabric treatment
EP2276506A4 (en) * 2008-04-30 2014-05-07 Immunogen Inc Potent conjugates and hydrophilic linkers
EP2610263A1 (en) * 2011-12-30 2013-07-03 Brossmer, Reinhard Sialic acid dimers
WO2014080251A1 (en) * 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
CN103933575B (en) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 A kind of three flute profile connexons and its application
WO2014197854A1 (en) * 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
CN107074879B (en) * 2013-09-02 2022-04-15 杭州多禧生物科技有限公司 Novel cytotoxic molecules for use in cell binding molecule-drug conjugates
CN103467590B (en) * 2013-09-02 2016-04-13 深圳大学 Bioconjugation body, the purine compound preparing it, synthetic method, medicinal preparations and its application in immunomodulatory

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101723961A (en) * 2009-12-08 2010-06-09 刘超美 Beta-lactam twin antibiotic compound, preparation method thereof and use thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A. S. HASHMI: "Photochemical Synthesis of Prochiral Dialkyl 3,3-Dialkylcyclopropene-1,2- dicarboxylates with Facial Shielding Substituents and Related Substrates", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 26 November 2001 (2001-11-26), GB, pages 4705 - 4732, XP055450906, ISBN: 978-0-08-097742-3 *
DIRK HEYL ET AL: "Facile Direct Synthesis of Acetylenedicarboxamides", SYNTHESIS, vol. 46, no. 11, 17 March 2014 (2014-03-17), STUTTGART, DE., pages 1463 - 1468, XP055450898, ISSN: 0039-7881, DOI: 10.1055/s-0033-1341101 *
GRETE VAN WUYTSWINKEL ET AL: "A convergent synthesis of heterocyclic dendrimers using the 1,3-dipolar cycloaddition reaction of organic azides and acetylenedicarboxylate esters", ROYAL CHEMICAL SOCIETY. JOURNAL. PERKIN TRANSACTIONS 1, vol. 1, no. 9, 1 January 2000 (2000-01-01), GB, pages 1337 - 1340, XP055450907, ISSN: 1470-4358, DOI: 10.1039/b000025f *
J. L. CHARLTON: "'Synthesis of chiral Esters of Acetylenedicarboxylic Acid'", TETRAHEDRON LETTERS, vol. 35, no. 34, 22 August 1994 (1994-08-22), pages 6243 - 6246, XP055450908 *
JOÃO P. M. NUNES ET AL: "Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC)", CHEMICAL COMMUNICATIONS, vol. 51, no. 53, 1 January 2015 (2015-01-01), pages 10624 - 10627, XP055539726, ISSN: 1359-7345, DOI: 10.1039/C5CC03557K *
JOHN A. MIKROYANNIDIS ET AL: "Synthesis, photophysics, structure-tunable photoluminescence, and electrochemical properties of soluble poly(p-phenylenevinylene)-based polymers with adjacent 1,3,4-oxadiazoles in the backbone", JOURNAL OF POLYMER SCIENCE, PART A: POLYMER CHEMISTRY, vol. 43, no. 14, 1 January 2005 (2005-01-01), US, pages 3079 - 3090, XP055450904, ISSN: 0887-624X, DOI: 10.1002/pola.20771 *
LOURDES CASTAÑEDA ET AL: "Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation", CHEMICAL COMMUNICATIONS, vol. 49, no. 74, 1 January 2013 (2013-01-01), pages 8187 - 8189, XP055539224, ISSN: 1359-7345, DOI: 10.1039/c3cc45220d *
RAVI V. J. CHARI ET AL: "Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 53, no. 15, 7 April 2014 (2014-04-07), pages 3796 - 3827, XP055167825, ISSN: 1433-7851, DOI: 10.1002/anie.201307628 *

Also Published As

Publication number Publication date
CN108811499B (en) 2021-09-24
EP3317246A2 (en) 2018-05-09
CN113698335A (en) 2021-11-26
CN108811499A (en) 2018-11-13
JP2018523639A (en) 2018-08-23
WO2015151080A2 (en) 2015-10-08
WO2015151080A3 (en) 2016-06-02
CA2991384C (en) 2022-11-08
CA2991384A1 (en) 2015-10-08
JP6700321B2 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
EP3317246A4 (en) Specific conjugation of a cell-binding molecule
EP3313857A4 (en) Polymer-cyclodextrin-lipid conjugates
EP3297649A4 (en) Peptide oligonucleotide conjugates
EP3206710A4 (en) Incretin-insulin conjugates
EP3319936A4 (en) Bridge linkers for conjugation of cell-binding molecules
EP3119885A4 (en) Antibody-fynomer conjugates
EP3137114B8 (en) Anti-ptk7 antibody-drug conjugates
EP3135358A4 (en) Top toy
EP3129357A4 (en) Affinity medicant conjugates
EP3334500A4 (en) Multi-ligand drug conjugates and uses thereof
EP3368033A4 (en) Honey-cannabinoid therapeutic composition
EP3388125A4 (en) Shooting-type toy
EP3525808A4 (en) Antibody-polymer-drug conjugates
EP3448417A4 (en) Insulin dimer-incretin conjugates
EP3302439A4 (en) Therapeutic composition
EP3220961A4 (en) Therapeutic vitamin d conjugates
EP3152223A4 (en) Peptide-drug conjugates
EP3261678B8 (en) Antibody-urease conjugates for therapeutic purposes
EP3703681A4 (en) Imipridones for gliomas
EP3268336A4 (en) Solid-rocket propellants
EP3496755A4 (en) Tgf- antagonist conjugates
EP3430033A4 (en) Insulin-incretin conjugates
EP3316885A4 (en) Antibody-sn-38 immunoconjugates with a cl2a linker
EP3347042A4 (en) Multivalent vlp conjugates
EP3001833A4 (en) Purification of nanoparticle-antibody conjugates

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180201

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07C0059760000

Ipc: A61K0047680000

A4 Supplementary search report drawn up and despatched

Effective date: 20190124

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/00 20060101ALI20190118BHEP

Ipc: C07K 16/28 20060101ALI20190118BHEP

Ipc: A61P 35/00 20060101ALI20190118BHEP

Ipc: C07C 237/52 20060101ALI20190118BHEP

Ipc: C07D 207/46 20060101ALI20190118BHEP

Ipc: A61P 37/00 20060101ALI20190118BHEP

Ipc: C07C 59/76 20060101ALI20190118BHEP

Ipc: C07D 417/14 20060101ALI20190118BHEP

Ipc: A61K 47/68 20170101AFI20190118BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200914

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516